Generate Biomedicines Financial Results
Generate Biomedicines reported third quarter 2026 financial results, highlighting a cash position of $404.2 million and progress in its Phase 3 asthma studies for GB-0895. The company also noted a significant collaboration with Zealand Pharma in obesity and metabolic diseases with total potential milestones of nearly $1.2 billion.
“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.”
Mike Nally, chief executive officer of Generate Biomedicines